Compare Gap Inc (GAP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Pfizer Inc — how do they compare? Gap Inc trades at $23.33 (market cap $8.29B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 19.3× Gap Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Pfizer Inc for 158 Days on average.
| GAP | PFE | |
|---|---|---|
Market Cap | $8.29B | $159.59B |
Volume | 5,470,564 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $29.02 |
52-Week Low | $18.35 | $23.67 |
Typical Hold Time | 37 Days | 158 Days |
Enterprise Value | $11.53B | $211.09B |
Dividend Yield | 2.96% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap (GAP) trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.11 and robust profitability, including a 33.78% ROE. Recent earnings beat estimates in Q1 and Q2 2026, and the company is expanding into music partnerships to engage customers. Cash flow from operations remains healthy at $1.49 billion for 2025.
The outlook is positive given Gap's attractive valuation, earnings momentum, and strategic initiatives. Key risks include competitive pressures in retail and reliance on brand revitalization. Analyst consensus is a $25.67 price target, suggesting upside potential, but investors should monitor execution of growth strategies amid economic uncertainties.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
